Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 9/20 | 0.71 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.50 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654106 | 0.86 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL221868 | 0.84 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2655128 | 0.81 | GABRG2 (0.73) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4347032 | 0.80 | ACACA (0.64) | NPC1RAB9AACACAENPP3ENPP1 | |
| SCHEMBL28196806 | 0.80 | ACACA (0.64) | NPC1RAB9AACACAENPP3ENPP1 | |
| Formaldehyde SCHEMBL27875050 | 0.79 | GABRG2 (0.88) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2653420 | 0.78 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL30661712 | 0.77 | NPC1 (0.62) | NPC1RAB9AACACAENPP3ENPP1 | |
| SCHEMBL29105359 | 0.77 | NPC1 (0.62) | NPC1RAB9AACACAENPP3ENPP1 | |
| SCHEMBL17283658 | 0.76 | CA4 (0.68) | NPC1RAB9AENPP3ENPP1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | claimed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | claimed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1532120-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004014865-A1 | PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235021-A1 | Phenylpyridazine derivatives as ligands for gaba receptors | GABRA5, GABRA2, GABRA3 | GABRG2 20/4885GABRB3 8/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.